1. HBW Insight
  2. >>Leadership

Pfizer elevates Bourla as Read steps down

Pfizer’s chief executive officer Ian Read is to step down after eight years at the helm of the US pharma giant and take on the role of executive chairman. On 1 January 2019, he will be succeeded by chief operating officer Albert Bourla, who won the “unanimous support” of Pfizer’s board.

Pfizer’s chief executive officer Ian Read is to step down after eight years at the helm of the US pharma giant and take on the role of executive chairman. On 1 January 2019, he will be succeeded by chief operating officer Albert Bourla, who won the “unanimous support” of Pfizer’s board.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

French Agency Proposes Effective EU Ban On CBD In Foods And Cosmetics

 
• By David Ridley

France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.

People On The Move: Appointments At Maxwellia, Nestlé, Alland & Robert

 
• By Tom Gallen

A round-up of the latest European health & wellness market moves: Maxwellia names chief operating officer; Nestle appoints marketing & sales head; Alland & Robert gets deputy general manager.

All US FDA Product Centers May Merge Under Planned Agency Reorganization

 
• By Sarah Karlin-Smith

Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.

Trump’s US FDA Takeover Similar To Flat Earth Proponents Running NASA, Woodcock Says

 
• By Sue Sutter

The former principal deputy commissioner said the “decapitation” of senior leadership will make resolving internal disputes more difficult, which will slow application reviews. Woodcock also called the FDA layoffs a slow-moving catastrophe.

More from HBW Insight

Azelis Grows Nutraceuticals Offering In Iberia With Solchem

 
• By Tom Gallen

Azelis adds dietary supplement ingredients and a large customer base across Spain to its portfolio with the acquisition of Solchem Nature.

Momentum Of Questions About Self-GRAS Meets Wall Of Exemption From ‘Rigorous Review’

 
• By Malcolm Spicer

HHS Secretary Kennedy ‘s opposition to allowing GRAS without notifications has support but also questions just as strong about whether FDA is authorized to conduct a rulemaking to eliminate the option.

Preamble ‘Poison Pill’ Could Haunt ACNU Switch Rule – House Energy And Commerce Members

 
• By Malcolm Spicer

Reps. Latta, Crenshaw and Miller-Meeks contend language in ACNU final rule preamble would allow a sponsor of an approved application to litigate to halt Rx availability of same formulation and “risk eliminating the very rule on which its product approval was based.”